STOCK TITAN

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Rhea-AI Summary

Avalo Therapeutics (AVTX) granted stock options to three new employees on November 18, 2026, as an inducement to join the company. The options cover 52,000 common shares in total at an exercise price of $6.70 per share, equal to the stock’s closing price on the grant date.

25% of the options vest one year after each employee’s start date, and the rest vest monthly over the following 36 months, subject to continued service through each vesting date. The compensation committee approved the grants under Nasdaq Listing Rule 5635(c)(4), and the options are subject to Avalo’s 2025 Inducement Award Plan and related award agreements.

Loading...
Loading translation...

Positive

  • None.

Negative

  • Minor point. Forward-looking: it has not happened yet and may not happen.Options on 52,000 common shares at $6.70 per share could dilute existing shareholders if exercised.

Key Figures

Options granted: 52,000 shares Exercise price: $6.70 per share Initial vesting: 25% +1 more
Options granted
52,000 shares
Aggregate awards to three new employees
Exercise price
$6.70 per share
Equal to the closing price on the grant date
Initial vesting
25%
On the applicable employee’s one-year employment anniversary
Remaining vesting period
36 months
Remaining shares vest monthly, subject to continued service

Historical Context

2 past events · Latest: Sep 29
2 events
  1. Sep 29

    Inducement grants

    24h Move
    -1.6%

    Prior grants used the same plan and 25%-then-monthly 36-month service-based vesting schedule.

  2. Sep 04

    Inducement grants

    24h Move
    +2.5%

    Prior grants used the same plan and 25%-then-monthly 36-month service-based vesting schedule.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nonstatutory stock options, nasdaq listing rule 5635(c)(4), mab
3 terms
nonstatutory stock options financial
"grants of nonstatutory stock options to purchase an aggregate of 52,000 shares"
A nonstatutory stock option is a company-issued right that lets an employee or contractor buy shares later at a set price, but it does not qualify for special tax breaks. Think of it like a voucher to buy stock at today’s price; when used, the difference between market price and voucher price is taxed as ordinary income to the holder. Investors care because these options create potential share dilution, affect reported compensation costs, and influence employee incentives and cash flow when taxes and withholdings are settled.
nasdaq listing rule 5635(c)(4) regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
mab medical
"lead anti-IL-1β monoclonal antibody (mAb) drug candidate"
A mAb (monoclonal antibody) is a lab-made protein designed to recognize and bind a specific target on cells or pathogens, like a custom-made key that fits one lock. Investors care because mAbs are often developed as therapies or diagnostic tools whose clinical trial results, regulatory approvals, production capacity, and patent status can drive significant revenue swings and affect a company’s valuation and risk profile.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

WAYNE, Pa., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to three new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 52,000 shares of common stock (the “Options”) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

The Options were granted on November 18, 2026, and have an exercise price of $6.70 per share, which is equal to the closing price of Avalo’s common stock on the grant date. The Options will vest as to 25% of the underlying shares of common stock on the one-year anniversary of the applicable employee’s start date of employment, and the balance of the underlying shares of common stock vesting monthly thereafter over 36 months, subject to the applicable employee’s continued service relationship with Avalo through the applicable vesting dates. The Options are subject to the terms and conditions of Avalo’s 2025 Inducement Award Plan and award agreements thereunder.

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Avalo is advancing its lead anti-IL-1β monoclonal antibody (mAb) drug candidate, abdakibart, into a phase 3 registrational program in hidradenitis suppurativa (HS), a chronic inflammatory skin condition that affects an estimated 1-4% of the population globally. Avalo is pursuing additional development opportunities in IL-1β driven indications. Avalo is also developing AVTX-010, a long-acting next-generation anti-IL-1β mAb. For more information about Avalo, please visit www.avalotx.com.

Forward-Looking Statements

This press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Avalo’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Avalo’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “might,” “will,” “could,” “would,” “should,” “continue,” “seeks,” “aims,” “predicts,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” or similar expressions (including their use in the negative), or by discussions of future matters such as: drug development costs, timing of trials and trial results and other risks, including reliance on investigators and enrollment of patients in clinical trials; reliance on key personnel; regulatory risks; general economic and market risks and uncertainties, including those caused by the war in Ukraine and the Middle East; and those other risks detailed in Avalo’s filings with the Securities and Exchange Commission, available at www.sec.gov. Actual results may differ from those set forth in the forward-looking statements. Except as required by applicable law, Avalo expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Avalo’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For media and investor inquiries
Jonathan Neely
VP, Head of Investor Relations
jneely@avalotx.com

or

Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares do Avalo Therapeutics’ employee inducement options cover, and what is the exercise price?

Avalo Therapeutics granted options covering 52,000 common shares at $6.70 per share to three new employees. The exercise price matched the stock’s closing price on the November 18, 2026 grant date.

When do Avalo Therapeutics’ employee inducement options vest?

The options vest 25% on each employee’s first start-date anniversary, with the balance vesting monthly over the following 36 months. Employees must remain in service with Avalo through each applicable vesting date.

Keep reading